Samsung has hundred of other biotech options they can consider. Many well managed biotechs with high potential pipelines. CyDy has failed most of it's trials or failed to have competitive results. Had a pack of legal problems that no company would want (including a near term bankruptcy filing). Has significant trial data credibility issues -- failed to have peer review publication of most of its trial results and more importantly had the FDA Statement clearly stating the company misrepresented and manipulated its CoV trial data.
CEO has been indicted twice and is now under SEC and DOJ investigation.
You can bet Samsung can find better acquisition candidates with a lot less fleas. Remember the last "partnerships" paid nothing -- Brazil, India (wherever they went), Philippines, American Regent (walked away). Only Vyera, the worst drug company in the U.S. paid anything and they gave it away to Regnum (who?), a foreign shell corporation with NO sales force.
News 
Market Data 
Discover 
